Head-To-Head Analysis: Upstream Bio (NASDAQ:UPB) vs. Organogenesis (NASDAQ:ORGO)

Upstream Bio (NASDAQ:UPB) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Profitability

This table compares Upstream Bio and Organogenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Organogenesis	-19.94%	-23.89%	-11.13%

Analyst Ratings

This is a breakdown of current ratings for Upstream Bio and Organogenesis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1	2	4	0	2.43
Organogenesis	1	2	0	0	1.67

Upstream Bio currently has a consensus price target of $29.67, suggesting a potential upside of 982.73%. Organogenesis has a consensus price target of $4.33, suggesting a potential upside of 336.30%. Given Upstream Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Upstream Bio is more favorable than Organogenesis.

Institutional & Insider Ownership

49.6% of Organogenesis shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 18.8% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Upstream Bio has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Valuation & Earnings

This table compares Upstream Bio and Organogenesis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$3.16 million	47.52	-$143.44 million	($2.90)	-0.94
Organogenesis	$564.17 million	0.23	$37.03 million	($0.86)	-1.15

Organogenesis has higher revenue and earnings than Upstream Bio. Organogenesis is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Organogenesis beats Upstream Bio on 8 of the 14 factors compared between the two stocks.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.